Status:
UNKNOWN
Study of DC-CIK to Treat NPC
Lead Sponsor:
Guangxi Medical University
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Concurrent of radiotherapy and chemotherapy is the main treatment method for patients with nasopharyngeal carcinoma (NPC). However, Relapse remains the major cause of treatment failure. A series of st...
Detailed Description
About 60 patients with staging Ⅱ-Ⅲ of NPC, after accepting concurrent radiotherapy and chemotherapy, will be randomly divided into group A (receive DC-CIK treatment) or group B (just regularly follow ...
Eligibility Criteria
Inclusion
- Patients with staging Ⅱ-Ⅲ of NPC;
- Patients who had completed concurrent of radiotherapy and chemotherapy;
- Patients who have a life expectancy of at least 12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status was 0-1;
- The bone marrow functioned normally (WBC \> 4.0×109/L, Hb \> 120 g/L, PLT \> 100×109/L);
- The ECG results were normal, and the liver and kidney were functional.
Exclusion
- Patients who had distant metastases by imaging studies;
- Patients with uncontrolled infection; underlying disease that was severe or life-threatening;
- Patients who were pregnant or lactating;
- ECOG perform status ≥ 2;
- Patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment.
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01821495
Start Date
May 1 2013
End Date
May 1 2018
Last Update
April 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangxi Medical University
Nanning, Guangxi, China, 530000